TPMP Rule Stalled: Build to the Standard Anyway

In the preamble to its proposed Tobacco Product Manufacturing Practice (TPMP) rule, FDA cited a study in which 9 of 21 e-liquid samples had nicotine levels deviating from the labeled value by more than 10%, "with inconsistencies ranging from -21 percent to +22.1 percent." FDA's concern was blunt: "Inadequate production processes and controls may also contribute to substantial variability in actual nicotine concentration as compared to labeled nicotine concentration in e-liquids intended to be used with ENDS." That proposed rule, published March 10, 2023, was the clearest signal the agency had sent about where quality expectations were heading for tobacco product manufacturing.

Then the rule slipped. After appearing in the Final Rule Stage on the Unified Regulatory Agenda through the Spring 2024 edition, it moved to "Long-Term Actions" in the Fall 2024 agenda and has stayed there since. The rule proposing 21 CFR Part 1120, which would impose design and development controls, process controls, and a master manufacturing record on tobacco product manufacturers, is stalled but not dead: the most recent agenda entry still carries a projected final rule date of July 2027.

Some manufacturers read that as a reprieve. They should not. The first authorized nicotine pouch PMTAs tell a different story about what FDA actually expects from manufacturers, regardless of whether the TPMP rule ever reaches final form.

What the TPMP Rule Proposed

The proposed rule, published at 88 FR 15174 under Docket No. FDA-2013-N-0227 (RIN 0910-AH91), laid out a comprehensive quality system framework for tobacco product manufacturing. The key subparts translate directly to operational requirements:

Subpart D: Design and Development Controls. This subpart contains two proposed sections: design and development activities, and the master manufacturing record (MMR) at proposed section 1120.44. Manufacturers would need documented design and development procedures for new and modified tobacco products, including a risk management process and design validation and verification. The MMR would hold the formulation, manufacturing instructions, specifications, and quality control procedures that make production reproducible and auditable. For nicotine pouch manufacturers, formulation development would require the rigor that pharmaceutical and medical device companies apply to their design processes.

Subpart E: Process Controls. The largest subpart, with nine proposed sections. Every production process affecting product quality would need documented procedures, validated processes, and monitoring controls, covering ingredient receiving through finished product release, including in-process testing and equipment qualification.

Subparts F, G, and H: Labeling, Handling, and Records. Subpart F covers packaging and labeling controls, Subpart G covers handling, storage, and distribution, and Subpart H covers recordkeeping and document controls, requiring records to be legible, contemporaneously recorded, original, and accurate.

Subpart I: Small Tobacco Product Manufacturers. FDA proposed that any final rule take effect two years after publication, and that small tobacco product manufacturers would not have to comply until four years after that effective date, giving them six years in total.

The estimated compliance cost: FDA's preliminary economic analysis put the mean present value of costs, annualized over ten years, at $27.0 million using a 7 percent discount rate and $28.2 million at 3 percent, against estimated annualized benefits of $27.2 million and $29.9 million. The underlying range is wide, from roughly $13 million to $54 million per year. Those figures cover the documentation, testing, and quality system infrastructure the rule would require across the regulated industry.

Why "Long-Term Action" Does Not Mean "Never"

The Unified Regulatory Agenda sorts rules into stages including Prerule, Proposed Rule, Final Rule, and Long-Term Actions. Long-Term Actions means the agency does not expect to take its next action within the next 12 months. It does not mean the rule is withdrawn, and here it plainly is not: the agenda entry still lists a projected final rule date of July 2027. It also does not mean the agency has abandoned its quality expectations.

Three factors suggest the TPMP standard is alive in practice even if the formal rule is stalled.

First, the authorized PMTAs demonstrate the standard implicitly. ZYN received marketing authorization in January 2025 for 20 products. Helix Innovations, an Altria company, received authorization in December 2025 for six on! PLUS products. Both came from large manufacturers with mature quality infrastructure, built long before any TPMP rule required it, because FDA's PMTA review process asks for the same kinds of documentation, process control, and traceability the rule would formalize. The specifics of either application are confidential, so the inference runs from what FDA demands of applicants generally, not from published detail about these two.

Second, the evidence that justified the rule did not disappear when the rule stalled. The nicotine labeling inconsistencies FDA cited in the preamble are still there. FDA continues to conduct post-market surveillance. Products with inconsistent nicotine delivery are products that fail the "appropriate for the protection of public health" standard under Section 910(c)(2) of the FD&C Act. Consistency problems will surface in PMTA reviews whether or not the TPMP rule is final.

Third, FDA is asking for TPMP concepts through the PMTA. At its February 10, 2026 roundtable on premarket submissions, FDA listed the quality system document problems it keeps encountering: standard operating procedures that "lack sufficient detail or are unclear," work instructions that "do not include acceptance criteria for in-process checks," and Certificates of Analysis "missing: target specification with units, quantitative acceptance criteria with units, test data average, either standard deviation or minimum and maximum values." FDA also tells applicants to include "in-process checks to ensure nicotine quantity is within specifications at each step." Those materials carry FDA's disclaimer that they do not represent Agency position or policy, but the concepts are TPMP's, arriving through a different door. A manufacturer answering them is demonstrating TPMP-equivalent controls.

The Authorized Pouch PMTAs Set the Implicit Benchmark

The ZYN and on! PLUS authorizations are not just regulatory milestones. They are public benchmarks for what a successful PMTA manufacturing package looks like.

PMTA contents are confidential, so nobody outside FDA can read these applications. What is public is what FDA said it found, and in both cases the agency emphasized constituent-level results: the authorized pouches contain "lower levels of most harmful and potentially harmful constituents (HPHCs) when compared to other oral and smokeless tobacco products, many of which were too low to be quantified." Reporting constituent levels below quantification limits, product after product, is not achievable without controlled inputs and reproducible processes. The quality system is inferred from the analytical result rather than published directly.

For manufacturers preparing their own applications, these authorizations set the competitive standard. FDA reviewers who have evaluated applications carrying that level of analytical rigor will read subsequent applications against that baseline. A manufacturer that submits a PMTA with informal quality practices and undocumented process controls is competing against applicants who have already demonstrated what "good" looks like.

The practical question is not whether TPMP will become law. The practical question is whether your manufacturing documentation will survive the same scrutiny that ZYN and on! PLUS applications received.

The Cost of Retrofitting After a Deficiency Letter

Building TPMP-equivalent controls proactively costs a fraction of retrofitting them under regulatory pressure. The math works in three dimensions.

Time. A deficiency letter carries a response deadline, and it is never long enough to build a quality system from nothing. Doing it while maintaining production is an emergency exercise that disrupts operations and diverts resources from revenue-generating work. Manufacturers who build these systems before submission get to phase implementation over months or years instead.

Money. FDA's annualized industry-wide compliance estimate is the cost of building systems correctly the first time. Retrofitting under pressure costs more because it requires expedited consulting, accelerated validation studies, and production slowdowns during implementation. Emergency quality system implementations also carry higher error rates, which can generate additional deficiency findings.

Risk. A PMTA application that receives a deficiency letter about manufacturing controls is an application that may never recover, and each round extends the review timeline. The spread between a clean submission and a contested one is visible in FDA's own record: the six on! PLUS pouches authorized in December 2025 cleared scientific review in three months, which FDA called a record for a PMTA, while ZYN's products came through what FDA described as "an extensive scientific review" measured in years. Every deficiency cycle pushes authorization further out, and during that time the product stays unauthorized while competitors with orders take share.

What TPMP-Equivalent Controls Look Like for Ingredient Sourcing

The TPMP rule's proposed requirements cascade through the supply chain. Manufacturers cannot demonstrate process controls if their incoming ingredient specifications are inconsistent. They cannot maintain a master manufacturing record if ingredient documentation changes format or content from lot to lot.

For nicotine, the primary active ingredient in pouch and e-liquid formulations, TPMP-equivalent sourcing means the following:

Consistent grade specifications. USP/EP grade nicotine provides the pharmacopoeial reference standard that TPMP's design and development control requirements anticipate. Each lot meets the same documented specification, which means the manufacturer's master manufacturing record remains valid across production batches without requiring re-qualification for each incoming lot.

Batch-level Certificates of Analysis. Process controls under Subpart E would require incoming materials to be verified against specifications before use. A CoA that includes assay percentage, full impurity profile, and grade certification for each specific batch is the documentation that satisfies incoming material verification. A generic CoA covering "typical" values is not sufficient for a quality system that must demonstrate batch-level traceability.

Salt form documentation for formulation consistency. Manufacturers using nicotine salts in pouch formulations need salt-form-specific documentation that connects the ingredient specification to the finished product's nicotine delivery profile. The TPMP design and development control requirements would make this connection explicit: the ingredient specification is a design input, and the finished product nicotine delivery is a design output that must be verified.

Stable supply chain traceability. The master manufacturing record proposed at section 1120.44 would include ingredient sourcing documentation. A supplier that provides full seed-to-shipment traceability produces the documentation that populates this section of the record. A supplier that provides only a CoA leaves the manufacturer to fill that gap independently.

Audit-ready manufacturing partner documentation. The proposed rule applies to tobacco product manufacturers rather than to ingredient suppliers, but process control obligations are only as good as the inputs they govern, so the expectation lands on suppliers in practice. GMP, ISO 9001, and HACCP certifications at the supplier's manufacturing partner facility provide the documented evidence that the ingredient supply chain meets the quality system expectations the TPMP rule would formalize.

Building Now vs. Waiting: A Decision Framework

Manufacturers evaluating whether to invest in TPMP-equivalent controls before the rule is finalized should consider three scenarios.

Scenario 1: The TPMP rule reaches final form on something like the projected 2027 timeline. Manufacturers who built proactively are already compliant. Manufacturers who waited absorb their share of the industry-wide compliance cost under deadline pressure, with competitors who prepared early gaining first-mover advantage in authorized product filings.

Scenario 2: The TPMP rule remains stalled indefinitely. Manufacturers who built proactively still benefit. Their PMTA applications contain stronger manufacturing documentation. Their production is more consistent, reducing waste and quality failures. Their quality systems meet the implicit benchmark set by the ZYN and on! PLUS authorizations. The investment was not wasted because the standard is being applied through PMTA review even without the rule.

Scenario 3: FDA replaces the TPMP rule with guidance or enforcement discretion. Even softer alternatives would reference the same quality system concepts. Design controls, process validation, and master manufacturing records are not TPMP inventions. They are established quality principles that FDA has applied to every other regulated product category. A guidance document would describe the same expectations in non-binding language.

In all three scenarios, the manufacturer who builds to the TPMP standard is better positioned. The only scenario where waiting is advantageous is one where FDA permanently abandons all manufacturing quality expectations for tobacco products. That scenario is not consistent with the agency's stated public health mission or its track record across other regulated industries.

The Ingredient Supplier's Role in TPMP Readiness

Nicotine ingredient suppliers occupy a specific position in the TPMP framework. The proposed rule targets manufacturers, not suppliers directly. But a manufacturer cannot demonstrate compliance with process controls, design and development controls, or master manufacturing record requirements if its primary active ingredient arrives without the documentation those controls demand.

This creates a practical filter. Manufacturers building TPMP-equivalent quality systems will select suppliers whose documentation supports that system. Suppliers who provide batch-level CoAs, traceability records, stability data, and audit-ready manufacturing partner credentials become quality system components. Suppliers who provide only a product and a price become liabilities.

FDA's decision to close its nicotine pouch PMTA pilot to new products while extending the pilot's efficiencies to all pouch reviews reinforces this dynamic. Faster reviews compress the time available to answer FDA's questions, so documentation quality at the ingredient level matters more, not less. TPMP readiness and PMTA readiness are, in practice, the same investment.

NicAlliance provides USP/EP grade nicotine with batch-level documentation, full supply chain traceability, and a certified US-based manufacturing partner whose quality credentials support TPMP-equivalent quality systems. If your quality team is evaluating ingredient suppliers against the TPMP benchmark, request a sample with full documentation and compare it against what your current supplier provides.

Frequently Asked Questions